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Ovarian cancer is the ﬁfth most common cancer in women, caus-
ing more deaths than any other cancer of the female reproductive
system. The American Cancer Society (2012) projects that there will
be 22,280 new cases of ovarian cancer in 2012, as well as 15,500
deaths. Mesotheliomas, however, are uncommon, with about 3000
new cases diagnosed per year in the United States, an incidence of
0.96 in 100,000 (Howlader et al., 2012). Approximately 9% of meso-
theliomas arise in the peritoneum and half are epithelial in origin
(Antman et al., 2005). Well-differentiated papillary mesothelioma
(WDPM) of the peritoneum, a variant of epithelial mesothelioma, is
a rare pathologic ﬁnding. It is considered by most to be of low malig-
nant potential, as described in a case report and a review of the liter-
ature by Hoekstra et al. (2005). Diagnosing WDPM concomitantly
with another malignancy is extraordinarily rare. Very few reports
have been published in the literature describingWDPM in association
with gynecologic malignancies, and most of these involve endometri-
al cancers. We present a case of endometrioid ovarian adenocarcino-
ma in association withWDPM, which has not yet been reported in the
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Ms. DF, a 50-year-old nulliparous Caucasian female, was noted to
have symptoms and clinical ﬁndings consistent with ovarian cancer
while hospitalized for an unrelated diagnosis. A gynecological history
revealed menometrorrhagia, abdominal pain, bloating, constipation,
and weight loss for the past six months. On exam, a midline, mobile
masswas noted above the umbilicus. CA 125was 40,442. A transvaginal
ultrasound showed bilateral complex ovarian masses with cystic and
solid components, a 4 cm irregular mass in the lower uterine segment,
and ascites.
One month later, surgical staging and debulking yielded intra-
operative ﬁndings of numerousmalignant appearing sheets of implants
with extensive coating of the large and small bowels, spleen, liver, dia-
phragm, and pelvic peritoneum. Thin, sheet-like disease coated thema-
jority of the small and large bowels, precluding optimal debulking. All
multidimensional bulky disease was resected. Final pathology revealed
negative pelvic washings and moderately to poorly differentiated ade-
nocarcinoma consistent with endometrioid type involving the left
ovary and fallopian tubewithmetastasis to the cervix and lower uterine
segment. Lymphovascular space invasion was noted. On the uterine se-
rosa, right ovary, large bowel, and small bowel therewasﬂorid papillary
mesothelial proliferation consistent with well-differentiated papillary
mesothelioma. A single nodule of metastatic adenocarcinoma was
noted on the omentum along with extensive ﬁbrous serosal adhesions
with well-differentiated papillary mesothelioma. These ﬁndings were
conﬁrmed in consultation with a gynecologic pathologist. An implant
on the omentum was sent for tumor sensitivity assays. Carboplatin
and gemcitabine were chosen for treatment.
Ms. DF tolerated 6 cycles of carboplatin and gemcitabine. Serial
CA 125 levels were followed, and they steadily decreased to 10.9
four months after surgical staging and debulking. A follow up CT
scan showed no evidence of disease ﬁve months after surgical
debulking. Consideration was given to a second look and hyperther-
mic intraperitoneal chemotherapy (HIPEC) but it was not opted for
by the patient. She chose to proceed with conservative management.Discussion
A diagnosis of concomitant endometrioid ovarian adenocarcinoma
and WDPM is extraordinarily rare, with this being the ﬁrst reported
case to our knowledge. It has been reported that WDPM and papillary
Fig. 3. Endometrioid adenocarcinoma of the ovary: cribriform glands with cuboidal to
columnar epithelium.
Fig. 1. Well-differentiated papillary mesothelium: mesothelial papillations containing
cores of ﬁbrovascular stroma.
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logical features making them histologically similar. WDPM is generally
associated with histological ﬁndings of coarse papillary architecture
withﬁbrovascular coreswith occasional areas of tubulopapillary pattern
(Hoekstra et al., 2005) (Fig. 1). Immunohistochemistry and electronmi-
croscopy can be used to conﬁrm the diagnosis of WDPM and differenti-
ate it from other histologically similar disease processes. Common
immunohistochemical stains that are sensitive and speciﬁc for the dif-
ferentiation of WDPM from other similar appearing pathologies are
calretinin (Fig. 2), MOC-31, and estrogen receptors (ER) (Ordóñez,
2006). In this case, a battery of immunostains including ER, PR,
calretinin, p53, p63, andWT1were performed, even though the ovarian
primarywas not of papillary serous histology. The endometrioid ovarian
cancer cells (Fig. 3) stained positive for p53, WT1, ER, and PR and
stained negative for calretinin. The mesothelial cells were positive for
calretinin and negative for p53, ER, and PR, conﬁrming the presence of
two separate diagnoses.
There are no formal recommendations for treatment of WDPM, es-
pecially when it is found in association with another primary cancer.
Carboplatin and gemcitabine were chosen for treatment, carboplatinFig. 2. Papillary mesothelioma: mesothelial lining cells strongly positive for calretinin.as the ﬁrst line against the endometrioid ovarian cancer and gemcitabine
for its effectiveness against epithelial ovarian cancers and mesothelioma.
This regimen seemed to be active against both primary neoplasms, as se-
rial CA 125 levels progressively decreased from 40,442 to 10.9 over four
months and follow up CT scan obtained three months after completion
of the chemotherapy regimen showed no evidence of disease, although
it is possible that the WDPM spontaneously regressed as previously
reported in the literature. After completion of the planned chemotherapy,
the patient was offered a second look laparotomywith HIPEC. HIPECwas
offered to the patient as the next line of treatment due to its support in the
literature, with potentially longer disease free survival and less transfor-
mation of WDPM into malignant processes after treatment with HIPEC.
Baratti et al. (2007) reported that cytoreduction and HIPEC with cisplatin
and doxorubicin seem more effective than debulking surgery in
preventing disease recurrence or transition or WDPM to aggressive
malignancy.
Information regarding progression and prognosis of WDPM are
lacking in the literature. While many reported cases portray WDPM
as a clinically benign tumor of low malignant potential, a few case re-
ports have described more aggressive behavior after long-term
follow-up. In one case, a patient died from a large embolism of
tumor cells to the pulmonary artery ﬁve years after diagnosis. At au-
topsy the patient had extensive retroperitoneal, anterior abdominal
wall, diaphragmatic, and pericardial invasion (Burrig et al., 1990). A
second case describes a patient who died of diffuse malignant meso-
thelioma approximately nine years after the diagnosis of WDPM,
suggesting a malignant transformation at some point in the clinical
course (Hejmadi et al., 2003). Cases describing more aggressive be-
havior seem to be in the minority, with a benign course or even spon-
taneous regression being more common with WDPM.
This case of endometrioid ovarian adenocarcinoma and concomi-
tant WDPM presented a challenge in the diagnosis, treatment, and
surveillance of Ms. DF and her disease. It is obvious that research is
needed to gain more information about the behavior, progression,
prognosis, treatment, and surveillance of patients diagnosed with
WDPM, whether alone or in association with a malignancy. Because
of its rarity, it will be difﬁcult to perform any prospective trials in
order to make recommendations regarding the management of
WDPM.Conﬂict of interest statement
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Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.gynor.2013.01.003.
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